Eve Todesco

Dr. Eve Todesco

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2025 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
RDRemy Dulery
Remy Dulery
VGVincent Guiraud
Vincent Guiraud
SCSylvain Choquet
Sylvain Choquet
CTCatherine Thieblemont
Catherine Thieblemont
EBEmmanuel Bachy
Emmanuel Bachy
RHRoch Houot
Roch Houot

24 June 2021 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
AMAlessandra Mazzola
Alessandra Mazzola
ETEve Todesco
Eve Todesco
SDSarah Drouin
Sarah Drouin
FHFanny Hazan
Fanny Hazan
SMStéphane Marot
Stéphane Marot
FCFilomena Conti
Filomena Conti
A low anti-spike antibody response of 28.6% was observed 28 days after BNT162b2 vaccine second dose among 133 solid organ transplant recipients without previous coronavirus disease 2019 (COVID-19). No serious adverse events were recorded. Four severe COVID-19 cases were reported between or after the 2 doses. Our data suggest to change the vaccine strategy.

22 December 2022 in Microorganisms
Verified
Journal Article
Open access
PDF file
TCThéophile Cocherie
Théophile Cocherie
KZKaren Zafilaza
Karen Zafilaza
VLValentin Leducq
Valentin Leducq
SMStéphane Marot
Stéphane Marot
VCVincent Calvez
Vincent Calvez
ETEve Todesco
Eve Todesco
SARS-CoV-2 expresses on its surface the Spike protein responsible for binding with the ACE2 receptor and which carries the majority of immunodominant epitopes. Mutations mainly affect this protein and can modify characteristics of the virus, giving each variant a unique profile concerning its transmissibility, virulence, and immune escape. The first lineage selected is the B.1 lineage characterized by the D614G substitution and from which all SARS-CoV-2 variants of concern have emerged. The first three variants of concern Alpha, Beta, and Gamma spread in early 2021: all shared the N501Y substitution. These variants were replaced by the Delta variant in summer 2021, carrying unique mutations like the L452R substitution and associated with higher virulence. It was in turn quickly replaced by the Omicron variant at the end of 2021, which has predominated since then, characterized by its large number of mutations. The successive appearance of variants of concern showed a dynamic evolution of SARS-CoV-2 through the selection and accumulation of mutations. This has not only allowed progressive improvement of the transmissibility of SARS-CoV-2, but has also participated in a better immune escape of the virus. This review brings together acquired knowledge about SARS-CoV-2 variants of concern and the impacts of the Spike mutations.

1 July 2017 in Antiviral Therapy
Verified
Journal Article
Closed access
ETEve Todesco
Eve Todesco
AMAlessandra Mazzola
Alessandra Mazzola
SASepideh Akhavan
Sepideh Akhavan
FAFlorence Abravanel
Florence Abravanel
TPThierry Poynard
Thierry Poynard
FCFilomena Conti
Filomena Conti
Hepatitis E virus (HEV) can induce chronic infections in the case of immunosuppression, which are sometimes not cured with ribavirin. Furthermore, sofosbuvir is a highly potent inhibitor of HCV polymerase and was shown to inhibit HEV genotype-3 replication in vitro. We report here the outcome of sofosbuvir/ribavirin therapy on a chronic HEV infection in a heart transplant recipient non-responder to ribavirin. After 24 weeks, the regimen failed to cure the persistent HEV infection, highlighting the need of therapeutic options for HEV-infected immunosuppressed patients.

4 June 2018 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
TNTHUY NGUYEN
THUY NGUYEN
DFDjeneba Bocar FOFANA
Djeneba Bocar FOFANA
MLM P Lê
M P Lê
CCC Charpentier
C Charpentier
GPG Peytavin
G Peytavin
AMAnne-Genevieve Marcelin
Anne-Genevieve Marcelin
Integrase strand transfer inhibitors (INSTIs) are recommended by international guidelines as first-line therapy in antiretroviral-naive and -experienced HIV-1-infected patients. This study aimed at evaluating the prevalence at failure of INSTI-resistant variants and the impact of baseline minority resistant variants (MiRVs) on the virological response to an INSTI-based regimen. Samples at failure of 134 patients failing a raltegravir-containing (n = 65), an elvitegravir-containing (n = 20) or a dolutegravir-containing (n = 49) regimen were sequenced by Sanger sequencing and ultra-deep sequencing (UDS). Baseline samples of patients with virological failure (VF) (n = 34) and of those with virological success (VS) (n = 31) under INSTI treatment were sequenced by UDS. Data were analysed using the SmartGene platform, and resistance was interpreted according to the ANRS algorithm version 27. At failure, the prevalence of at least one INSTI-resistant variant was 39.6% by Sanger sequencing and 57.5% by UDS, changing the interpretation of resistance in 17/134 (13%) patients. Among 53 patients harbouring at least one resistance mutation detected by both techniques, the most dominant INSTI resistance mutations were N155H (45%), Q148H/K/R (23%), T97A (19%) and Y143C (11%). There was no difference in prevalence of baseline MiRVs between patients with VF and those with VS. MiRVs found at baseline in patients with VF were not detected at failure either in majority or minority mutations. UDS is more sensitive than Sanger sequencing at detecting INSTI MiRVs at treatment failure. The presence of MiRVs at failure could be important to the decision to switch to other INSTIs. However, there was no association between the presence of baseline MiRVs and the response to INSTI-based therapies in our study.

1 February 2021 in Infectious Diseases Now
Verified
Journal Article
Closed access
LNL. Noël
L. Noël
RTR. Tubiana
R. Tubiana
ASA. Simon
A. Simon
MVM.-A. Valantin
M.-A. Valantin
RPR. Palich
R. Palich
ETEve Todesco
Eve Todesco